Cliff Brangwynne (Nereid)

One of biotech's flashiest star­tups is fi­nal­ly get­ting some com­pe­ti­tion from a pi­o­neer in a brand new field

Amir Nashat fi­nal­ly has some com­pe­ti­tion.

Near­ly two years ago, Po­laris’ man­ag­ing part­ner pulled to­geth­er $60 mil­lion and some high-pro­file ad­vi­sors to launch Dew­point Ther­a­peu­tics around a new ap­proach to bi­ol­o­gy, called bio­mol­e­c­u­lar con­den­sates. Op­er­at­ing as the on­ly biotech in the space since, they’ve land­ed big-mon­ey part­ner­ships with Bay­er and Mer­ck, more ven­ture cash and a cou­ple more mar­quee board mem­bers.

Endpoints News

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters